Cipla Ltd Gains 1.58%: 3 Key Drivers Behind This Week’s Momentum
2026-11-21 17:01:13Key Events This Week 16 Nov: Week opens at Rs.1,394.00 with marginal gain 18 Nov: Intraday high of Rs.1,425.00 with 3.17% surge 18 Nov: Surge in call option activity near Rs.1,430 strike 18 Nov: Sharp 31.74% jump in derivatives open interest 20 Nov: Week closes at Rs.1,414.95, up 1.58% Week Open Rs.1,394.00</d...
Read MoreP/E at 36.8 vs Industry's 39.5: What the Data Shows for Cipla Ltd.
2026-11-20 09:20:44Valuation Picture: A Slight Discount to Industry P/E The current P/E of 36.84 for Cipla Ltd. represents a modest discount of approximately 6.8% relative to the sector average of 39.53. This suggests that the market is pricing the stock with a slightly more cautious outlook compared to its peers. Given the pharmaceutical sector’s typical premium valuations driven by innovation and patent portfolios, Cipla’s valuation indicates tempered expectations, possibly reflecting recent performance challenges or sector headwinds. Cipla Ltd.’s large-cap status with a market capitalisation of...
Read MoreP/E at 36.94 vs Industry's 39.30: What the Data Shows for Cipla Ltd.
2026-11-19 09:20:47Valuation Picture: Discount to Industry P/E Cipla Ltd. currently trades at a P/E of 36.94, which is approximately 6.1% below the Pharmaceuticals & Biotechnology industry average of 39.30. This discount suggests that the market is pricing in either a relatively subdued growth outlook or concerns over near-term earnings momentum compared to its sector peers. Given the sector’s average valuation, Cipla’s lower P/E could be interpreted as a valuation cushion, but it also raises questions about the sustainability of its earnings trajectory. Cipla Ltd.’s market capitalisation stands a...
Read More
Cipla Ltd Sees Sharp Surge in Derivatives Open Interest Amid Bullish Momentum
2026-11-18 15:00:28Cipla Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in open interest (OI) in its derivatives segment on 18 Nov 2026, signalling heightened market interest and potential directional bets. The stock outperformed its sector peers and broader indices, reflecting renewed investor confidence amid evolving market positioning.
Read More
Cipla Ltd Sees Sharp Open Interest Surge Signalling Renewed Market Interest
2026-11-18 14:00:21Cipla Ltd., a leading pharmaceutical and biotechnology company, witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market interest and potential directional bets. The stock outperformed its sector and broader indices, supported by robust volume and positive price action, prompting a reassessment of its market positioning and outlook.
Read More
Cipla Ltd Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity
2026-11-18 13:00:15Cipla Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market interest and potential directional bets. The stock outperformed its sector and broader indices, supported by strong volume and positive price action, reflecting a shift in investor positioning and sentiment.
Read More
12,969 Call Contracts Traded on Cipla Ltd. as Stock Edges Closer to Rs 1,430 Strike
2026-11-18 13:00:06On 18 Nov 2026, Cipla Ltd. witnessed significant call option activity with 12,969 contracts traded at the Rs 1,430 strike price, closely aligned with the stock’s closing price of Rs 1,424.60. This synchronisation between the derivatives and cash markets highlights a focused directional stance ahead of the 23 Nov expiry.
Read More
Cipla Ltd Sees Sharp Open Interest Surge Amid Bullish Derivatives Activity
2026-11-18 12:00:13Cipla Ltd., a leading player in the Pharmaceuticals & Biotechnology sector, witnessed a notable surge in open interest (OI) in its derivatives segment on 18 Nov 2026, signalling increased market participation and potential directional bets. The stock outperformed its sector peers and broader indices, reflecting renewed investor confidence amid evolving market dynamics.
Read More
Cipla Ltd. Surges 3.17% to Day's High of Rs 1425 — Outperforms Sector by 2.67 Percentage Points
2026-11-18 11:31:31The Sensex declined 0.41% on 18 Nov 2026, yet Cipla Ltd. surged 3.17%, outperforming its Pharmaceuticals & Biotechnology sector by 2.67 percentage points. This strong single-session gain stands out as a stock-specific event amid a broadly weaker market environment.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
17-Nov-2026 | Source : BSENewspaper advertisement for Notice of Postal Ballot and e-voting information.
Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge Long Island New York USA
17-Nov-2026 | Source : BSEPlease find enclosed intimation
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
16-Nov-2026 | Source : BSEPostal Ballot Notice dated 27th October 2026.
Corporate Actions
No Upcoming Board Meetings
Cipla Ltd. has declared 650% dividend, ex-date: 05 Jun 26
No Splits history available
Cipla Ltd. has announced 3:2 bonus issue, ex-date: 24 Apr 06
No Rights history available